Rosemont agrees to buy Aytu BioPharma to accelerate US expansion
The Leeds-based pharmaceutical company has agreed to pay $2.70 per share in cash for Aytu, adding CNS medicines and an established US commercial platform.

Rosemont Pharmaceuticals has agreed to acquire Nasdaq-listed Aytu BioPharma for $2.70 per share in cash, using an established US specialty medicines business to accelerate its American expansion. Announced on November 16, the proposed transaction would add an attention-deficit/hyperactivity disorder (ADHD) portfolio, a major depressive disorder medicine and US commercial capabilities.
The Leeds-headquartered company expects the deal to close in late December 2026, subject to the tender offer conditions being satisfied or waived. The offer represents a 41.1% premium to Aytu’s 30-day volume-weighted average share price and, according to Aytu’s announcement, a 51.7% premium to its closing price on November 13.
Buying commercial reach, not just medicines
For Rosemont, the acquisition is an expansion of an existing US presence rather than a first market entry. Its strategic value lies in combining Aytu’s portfolio and commercial capabilities—including omnichannel and digital marketing expertise—with Rosemont’s product development, regulatory and manufacturing operations.
Aytu focuses on medicines for complex central nervous system diseases. Its prescription products include ADHD treatments and EXXUA, or gepirone extended-release tablets, for major depressive disorder. Rosemont describes the transaction as bringing together an established ADHD portfolio and an emerging depression asset, alongside a US commercial platform.
That makes the deal more than a product acquisition: Rosemont would also gain the capabilities behind Aytu’s US specialty pharmaceutical business. The buyer says the combination is intended to accelerate growth, expand its reach and create opportunities across international markets. The announcement does not quantify expected revenue benefits or cost savings.
“Aytu has built an established CNS adult and paediatric-focused specialty pharmaceutical business with talented people, a differentiated portfolio and proven commercial capabilities,” said Alok Sonig, Rosemont’s chief executive. He said combining those capabilities with Rosemont’s expertise could provide a platform for future growth.
A UK formulation specialist broadens its US business
Rosemont specialises in developing, manufacturing and supplying oral liquid medicines. For nearly 60 years, it has focused on alternative dosage forms for patients who may have difficulty swallowing solid medicines. It serves international markets through a portfolio of licensed medicines spanning multiple therapeutic areas.
The proposed acquisition would bring that formulation-focused business together with Aytu’s CNS and paediatric portfolio. Aytu chief executive Josh Disbrow said the companies saw a strategic fit between his company’s products and Rosemont’s experience in developing and commercialising specialty medicines.
Rosemont is backed by Inflexion, the European-headquartered mid-market private equity firm. Inflexion’s stated approach includes supporting acquisitions and international expansion; it established an on-the-ground New York team in 2025. The announcement did not disclose a total transaction value or acquisition financing details.
Tender offer sets the route to completion
A wholly owned Rosemont subsidiary will launch a tender offer for all outstanding Aytu common shares. Completion requires, among other conditions, shares representing at least a majority of those outstanding to be tendered, and the exercise or termination of certain warrants. A second-step merger would acquire remaining shares at the same price, except those subject to properly exercised appraisal rights.
Aytu’s board unanimously approved the transaction. Its executive officers, directors and certain shareholders affiliated with Nantahala Capital Management and Stonepine Capital Management have signed tender and support agreements. Rosemont intends to launch the offer within 10 business days of the announcement.
Until completion, the companies will operate independently. Rosemont says its priorities after closing will include a smooth transition and continuity of supply and service for customers and partners. Those commitments place operational continuity alongside commercial expansion as the immediate test of the acquisition.


